|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.31 USD | +0.37% |
|
-1.67% | +41.05% |
| Market Cap | 3.01B 2.63B 2.43B 2.23B 4.22B 289B 4.3B 28.95B 11.36B 141B 11.29B 11.05B 487B | P/E 2026 * |
-8.83x | P/E 2027 * | -8.77x |
|---|---|---|---|---|---|
| Enterprise Value | 2.42B 2.12B 1.95B 1.8B 3.4B 233B 3.46B 23.33B 9.15B 114B 9.1B 8.9B 393B | EV / Sales 2026 * |
920x | EV / Sales 2027 * | 209x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | +0.37% | ||
| 1 week | -1.67% | ||
| Current month | +2.96% | ||
| 1 month | +19.27% | ||
| 3 months | +13.11% | ||
| 6 months | +49.12% | ||
| Current year | +41.05% |
| 1 week | 37.51 |  | 39.22 |
| 1 month | 32.26 | | 40.3 |
| Current year | 22.33 | | 40.3 |
| 1 year | 19.72 | | 40.3 |
| 3 years | 14.4 | | 53.18 |
| 5 years | 14.4 | | 57.2 |
| 10 years | 1.5 | | 75.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-25 | Free | Director | 26,000 | 0.0331% | ||
| 06-25 | Free | Founder | 115,000 | 0.1465% | ||
| 06-25 | Free | Director | 26,000 | 0.0331% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.37% | -1.67% | +67.66% | +2.74% | 3.01B | |
| -0.17% | +1.47% | +3.16% | +6.80% | 50.35B | |
| -0.29% | -2.81% | +387.81% | +591.82% | 39.21B | |
| -0.49% | +1.48% | +31.16% | -6.46% | 34.52B | |
| +1.53% | +3.11% | +15.41% | +58.54% | 34.6B | |
| +1.68% | -0.62% | +3.30% | +27.34% | 27.05B | |
| +1.13% | -3.11% | - | - | 16.68B | |
| -1.29% | -0.52% | +69.24% | +117.60% | 15.11B | |
| +0.43% | +3.34% | +14.96% | +17.46% | 13.85B | |
| +2.45% | +3.99% | +18.20% | -30.12% | 13.18B | |
| Average | +0.53% | +0.68% | +67.88% | +87.30% | 24.76B | |
| Weighted average by Cap. | +0.40% | +0.80% | +81.26% | +120.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.63M 2.3M 2.12M 1.95M 3.7M 254M 3.76M 25.37M 9.95M 124M 9.89M 9.68M 427M | 11.96M 10.46M 9.65M 8.87M 16.8M 1.15B 17.09M 115M 45.19M 563M 44.92M 43.94M 1.94B |
| Net income | -330M -289M -266M -245M -464M -31.76B -472M -3.18B -1.25B -15.52B -1.24B -1.21B -53.5B | -370M -324M -299M -275M -520M -35.65B -529M -3.57B -1.4B -17.42B -1.39B -1.36B -60.06B |
| Net Debt | -584M -511M -471M -433M -821M -56.2B -835M -5.62B -2.21B -27.47B -2.19B -2.15B -94.69B | -507M -444M -409M -376M -713M -48.82B -725M -4.89B -1.92B -23.86B -1.91B -1.86B -82.25B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/07/26 | $38.31 | +0.37% | 534,208 |
| 14/07/26 | $38.17 | -0.93% | 702,069 |
| 13/07/26 | $38.53 | -1.48% | 660,189 |
| 10/07/26 | $39.11 | +0.33% | 694,010 |
| 09/07/26 | $38.98 | +0.05% | 612,506 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CLDX Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
